Comparative effects of teriparatide and risedronate in glucocorticoid-induced osteoporosis in men: 18-month results of the EuroGIOPs trial - Wikidata - awgldk - TriplyDB

Comparative effects of teriparatide and risedronate in glucocorticoid-induced osteoporosis in men: 18-month results of the EuroGIOPs trial

Comparative effects of teriparatide and risedronate in glucocorticoid-induced osteoporosis in men: 18-month results of the EuroGIOPs trial

http://www.wikidata.org/entity/Q37001737

about

PINP as a biological response marker during teriparatide treatment for osteoporosis Prevention and treatment of bone changes associated with exposure to glucocorticoids Long-term safety of antiresorptive treatment: bone material, matrix and mineralization aspects Management of glucocorticoid-induced osteoporosis: clinical data in relation to disease demographics, bone mineral density and fracture risk.Advanced CT based in vivo methods for the assessment of bone density, structure, and strength.Prevention of glucocorticoid induced bone changes with beta-ecdysone.Bisphosphonates and glucocorticoid-induced osteoporosis: cons.More than 6 Months of Teriparatide Treatment Was More Effective for Bone Union than Shorter Treatment Following Lumbar Posterolateral Fusion Surgery.Long-term safety, efficacy, and patient acceptability of teriparatide in the management of glucocorticoid-induced osteoporosis.Once-weekly teriparatide improves glucocorticoid-induced osteoporosis in patients with inadequate response to bisphosphonates.Accuracy of finite element analyses of CT scans in predictions of vertebral failure patterns under axial compression and anterior flexion Sclerostin-antibody treatment of glucocorticoid-induced osteoporosis maintained bone mass and strength.One-year effects of glucocorticoids on bone density: a meta-analysis in cohorts on high and low-dose therapy Early changes in biochemical markers of bone formation during teriparatide therapy correlate with improvements in vertebral strength in men with glucocorticoid-induced osteoporosis Very high frequency of fragility fractures associated with high-dose glucocorticoids in postmenopausal women: A retrospective study.Review of new guidelines for the management of glucocorticoid induced osteoporosis.The effect of zoledronic acid on the fracture risk in men with osteoporosis.Safety issues and adverse reactions with osteoporosis management.Efficacy of osteoporosis pharmacotherapies in preventing fracture among oral glucocorticoid users: a network meta-analysis.Parathyroid Hormone and Parathyroid Hormone-Related Protein Analogs in Osteoporosis Therapy.Finite Element Analysis of Denosumab Treatment Effects on Vertebral Strength in Ovariectomized Cynomolgus Monkeys.[Male osteoporosis].Bone Tissue Properties Measurement by Reference Point Indentation in Glucocorticoid-Induced Osteoporosis.Glucocorticoid-induced osteoporosis: pathophysiological role of GH/IGF-I and PTH/VITAMIN D axes, treatment options and guidelines.Romosozumab: from basic to clinical aspects.Effects of alendronate and alfacalcidol on bone in patients with myasthenia gravis initiating glucocorticoids treatment.Short-term daily teriparatide in patients with rheumatoid arthritis.Glucocorticoids, Inflammation and Bone.Glucocorticoid-Induced Osteoporosis.Glucocorticoid-induced Osteoporosis.

P2860

Q26859267-E91CCE10-021D-498E-AF3E-C0E3E938EF7F Q26861474-8227EA37-9AB0-454B-80BB-6123F45FE975 Q27025945-569DF696-16AC-423A-9772-E1E0110AC56F Q30946308-8AF126AD-C00F-4843-8529-D7A752896921 Q34742707-9D5B4F07-6977-454D-A32D-B4750008A854 Q35163490-81FB66B5-70F5-409A-9CE8-A4D40A5ED6A2 Q35882427-4932C255-5E28-4CA3-A839-B0A08034920F Q35909167-469084C0-494F-4F89-A23C-AA28BAE202B5 Q36873339-4CD978D0-0233-41DE-AAFC-2D6EB262D6A4 Q37083734-218C2DB4-51EC-4946-9399-27D124AECF06 Q37113984-CA61CEE7-0050-40B8-A48F-31C63E14883E Q37119856-EBEE122F-776D-4FDF-80DB-1007B42A9590 Q37251693-5F870F18-29C4-4547-A803-0A088BF07756 Q37337557-69C48741-0083-42D5-9E3B-CD3F409497E0 Q37720586-86935BB5-1BD9-4922-9081-896B03A6F54E Q38151513-FD020757-B0BC-4F43-870B-632F7C2C9457 Q38182950-2F65C123-6429-41E2-8E21-90EA8C6FEA36 Q38677822-C44060C1-05A2-45EB-B4F0-E6783220E527 Q38702184-34FDAFC7-2FAA-4506-B8B1-CFA69887E0F0 Q39183207-B8A70D34-9D26-4C98-9A17-451C7D8C2FE0 Q39791628-EDF46BAD-DB46-4B1C-A106-B0CF3940B9DE Q40780710-8FF94E2B-CC62-430F-AEC0-FF1181030025 Q43509107-C0AB283B-E9FE-438B-9170-300AA6615805 Q45045554-F84AA1F8-A29D-4B98-AE0F-D94EF492E36D Q45424127-233A45B4-51D1-41C7-8412-9FDB3713358C Q48368605-7B2E36B0-3062-484F-9BC0-2A7D9C72598E Q48694023-9BAAAF7E-1893-4C6B-B621-A9D8B342C403 Q50128187-3BA30549-17DB-4630-809F-4AD599F0121C Q51093091-89387C08-A821-4FE3-87C6-E48A1849BEE7 Q55383510-AD6627EC-A512-4BF0-A274-0B419DD2473D

P2860

Comparative effects of teriparatide and risedronate in glucocorticoid-induced osteoporosis in men: 18-month results of the EuroGIOPs trial

http://www.wikidata.org/entity/Q37001737

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on June 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Comparative effects of teripar ...... results of the EuroGIOPs trial

@en

Comparative effects of teripar ...... esults of the EuroGIOPs trial.

@nl

type

label

Comparative effects of teripar ...... results of the EuroGIOPs trial

@en

Comparative effects of teripar ...... esults of the EuroGIOPs trial.

@nl

prefLabel

Comparative effects of teripar ...... results of the EuroGIOPs trial

@en

Comparative effects of teripar ...... esults of the EuroGIOPs trial.

@nl

P1433

Q37001737-0CA6DDAD-E2CE-42C8-B348-6663D47FFBF3

P1476

Q37001737-01612AE5-61ED-461C-A29F-5D9EA751D590

P2093

Q37001737-03F62DFC-66EC-4F12-95EB-740269C7DF74

Q37001737-1494A554-2501-48B3-BEC9-1E3E1400C97F

Q37001737-1BB997F4-78CE-43E2-A1CE-A802C2874C54

Q37001737-22639CD6-A0CF-42CF-B805-71A95C53A571

Q37001737-263910DD-B753-4EF8-BCFE-84064F6A5FC0

Q37001737-2D45A48A-DA56-430A-BADB-13390D555F34

Q37001737-4D7F32FA-B6A9-4372-96A6-02B3D73734C6

Q37001737-4F39F044-6433-4290-977A-0A29A2A20930

Q37001737-540E709D-0023-4ED7-A384-1F01D6E01FBB

Q37001737-5A359145-7B18-4A53-B5C5-9987AC0BC022

P2860

Q37001737-0474BB63-00E7-4C51-AD12-8AEA44C33166

Q37001737-0CBB5F6B-9A2A-47E8-8B80-AF5309D08595

Q37001737-0D5C5993-2652-4D9B-81FB-8A8392CCBEC4

Q37001737-14F74A4C-E8BF-4453-83A8-BD118E407262

Q37001737-15E96B13-6550-414E-B4E1-3EB54EB76838

Q37001737-1626F259-FFDC-4868-89C1-29F051BCB510

Q37001737-1A2428EC-C197-4680-BEC7-73EBE8F1F36B

Q37001737-1E4F48F8-A077-4563-9FF7-D7EFA3E74858

Q37001737-2657B775-4E05-461E-B375-B29B3B83919C

Q37001737-267AF9C4-BFC2-49A7-A281-8DDBB5817E3A

P304

Q37001737-4A7E48BF-9238-44CE-A52A-C79A9320A84B

P31

Q37001737-39BB9942-9F4B-40C7-9A71-8A9C3B947CD1

P356

Q37001737-B60C2DB3-1861-4EDB-87A2-04E48F15795F

P433

Q37001737-C0B18060-BEAE-42A0-A3FC-6390DB0247F0

P478

Q37001737-2335EC36-9B54-4712-A13B-3A18BD97BEE8

P577

Q37001737-253965D8-EF42-4901-958B-8C005DCCDBFE

P5875

Q37001737-5D305203-159C-4979-8FFA-35ACC71B07C0

P698

Q37001737-19F2858D-89A9-4799-9986-65F688F17E48

P921

Q37001737-46AEEE11-B507-4956-A212-C727875E7537

P932

Q37001737-0D4ED431-A27D-4C95-8AE2-D655EF3F9741

P356

P1433

Journal of Bone and Mineral Research

P1476

Comparative effects of teripar ...... results of the EuroGIOPs trial

@en

P2093

Andreas Reisinger

http://www.w3.org/2001/XMLSchema#string

Beatriz Sanz

http://www.w3.org/2001/XMLSchema#string

Christian Graeff

http://www.w3.org/2001/XMLSchema#string

Christopher Niedhart

http://www.w3.org/2001/XMLSchema#string

Claus-C Glüer

http://www.w3.org/2001/XMLSchema#string

Emilio Martín-Mola

http://www.w3.org/2001/XMLSchema#string

Federico Hawkins

http://www.w3.org/2001/XMLSchema#string

Fernando Marin

http://www.w3.org/2001/XMLSchema#string

Friederike Thomasius

http://www.w3.org/2001/XMLSchema#string

Georgios Kapetanos

http://www.w3.org/2001/XMLSchema#string

P2860

Bone microarchitecture in males with corticosteroid-induced osteoporosis.

Early responsiveness of women with osteoporosis to teriparatide after therapy with alendronate or risedronate

Effects of teriparatide, alendronate, or both in women with postmenopausal osteoporosis

Use of oral corticosteroids and risk of fractures.

Effects of two years of daily teriparatide treatment on BMD in postmenopausal women with severe osteoporosis with and without prior antiresorptive treatment.

Teriparatide or alendronate in glucocorticoid-induced osteoporosis.

Advances in glucocorticoid-induced osteoporosis

Accuracy of volumetric bone mineral density measurement in high-resolution peripheral quantitative computed tomography.

Prediction of new clinical vertebral fractures in elderly men using finite element analysis of CT scans.

The pathogenesis, epidemiology and management of glucocorticoid-induced osteoporosis.

P304

1355-1368

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/JBMR.1870

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

28

http://www.w3.org/2001/XMLSchema#string

P577

2013-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

234142486

http://www.w3.org/2001/XMLSchema#string

P698

23322362

http://www.w3.org/2001/XMLSchema#string

P921

P932

3708101

http://www.w3.org/2001/XMLSchema#string